These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18171334)

  • 1. A comparison of serum antivenom concentrations after intravenous and intramuscular administration of redback (widow) spider antivenom.
    Isbister GK; O'Leary M; Miller M; Brown SG; Ramasamy S; James R; Schneider JS
    Br J Clin Pharmacol; 2008 Jan; 65(1):139-43. PubMed ID: 18171334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised controlled trial of intramuscular vs. intravenous antivenom for latrodectism--the RAVE study.
    Isbister GK; Brown SG; Miller M; Tankel A; Macdonald E; Stokes B; Ellis R; Nagree Y; Wilkes GJ; James R; Short A; Holdgate A
    QJM; 2008 Jul; 101(7):557-65. PubMed ID: 18400776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, randomized trial of intravenous versus intramuscular antivenom for red-back spider envenoming.
    Ellis RM; Sprivulis PC; Jelinek GA; Banham ND; Wood SV; Wilkes GJ; Siegmund A; Roberts BL
    Emerg Med Australas; 2005 Apr; 17(2):152-6. PubMed ID: 15796730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of i.v. administration of redback spider antivenom.
    Isbister GK
    Intern Med J; 2007 Dec; 37(12):820-2. PubMed ID: 18028082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Red-back spider (Latrodectus hasselti) antivenom prevents the toxicity of widow spider venoms.
    Graudins A; Padula M; Broady K; Nicholson GM
    Ann Emerg Med; 2001 Feb; 37(2):154-60. PubMed ID: 11174232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antivenom use in Australia. Premedication, adverse reactions and the use of venom detection kits.
    Sutherland SK
    Med J Aust; 1992 Dec 7-21; 157(11-12):734-9. PubMed ID: 1360618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Red back spider bite.
    Poolman C; Lai E; Qld W
    Aust Fam Physician; 2007 May; 36(5):295. PubMed ID: 17536253
    [No Abstract]   [Full Text] [Related]  

  • 8. Evolution in the choice of therapies used to treat latrodectism: Redback spider antivenom or standard analgesic medications. Nothing to rave about.
    Sulaeman SJ; Graudins A
    Emerg Med Australas; 2023 Aug; 35(4):630-635. PubMed ID: 36807536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latrodectism: a prospective cohort study of bites by formally identified redback spiders.
    Isbister GK; Gray MR
    Med J Aust; 2003 Jul; 179(2):88-91. PubMed ID: 12864719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spider bite--the redback spider and its relatives.
    Nimorakiotakis B; Winkel KD
    Aust Fam Physician; 2004 Mar; 33(3):153-7. PubMed ID: 15054982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Latrodectism: case report of a katipo spider (Latrodectus katipo) bite and review of the literature.
    Thatcher L; Janes R
    N Z Med J; 2012 Mar; 125(1351):92-4. PubMed ID: 22426614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled trial of a highly purified equine F(ab)2 antibody black widow spider antivenom.
    Dart RC; Bogdan G; Heard K; Bucher Bartelson B; Garcia-Ubbelohde W; Bush S; Arnold T; Clark RC; Hendey GW; Holstege C; Spradley EA
    Ann Emerg Med; 2013 Apr; 61(4):458-67. PubMed ID: 23380292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examination of adverse events following black widow antivenom use in California.
    Nordt SP; Clark RF; Lee A; Berk K; Lee Cantrell F
    Clin Toxicol (Phila); 2012 Jan; 50(1):70-3. PubMed ID: 22175789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure of intramuscular antivenom in Red-back spider envenoming.
    Isbister GK
    Emerg Med (Fremantle); 2002 Dec; 14(4):436-9. PubMed ID: 12534488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial of intravenous antivenom versus placebo for latrodectism: the second Redback Antivenom Evaluation (RAVE-II) study.
    Isbister GK; Page CB; Buckley NA; Fatovich DM; Pascu O; MacDonald SP; Calver LA; Brown SG;
    Ann Emerg Med; 2014 Dec; 64(6):620-8.e2. PubMed ID: 24999282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization of Latrodectus mactans and L. hesperus venom by redback spider (L. hasseltii) antivenom.
    Daly FF; Hill RE; Bogdan GM; Dart RC
    J Toxicol Clin Toxicol; 2001; 39(2):119-23. PubMed ID: 11407496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Route of administration of redback spider bite antivenom: determining clinician beliefs to facilitate Bayesian analysis of a clinical trial.
    Brown SG; Isbister GK; Stokes B
    Emerg Med Australas; 2007 Oct; 19(5):458-63. PubMed ID: 17919219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards rationalisation of antivenom use in funnel-web spider envenoming: enzyme immunoassays for venom concentrations.
    Miller M; O'Leary MA; Isbister GK
    Clin Toxicol (Phila); 2016 Mar; 54(3):245-51. PubMed ID: 26678882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of venom antigenaemia and antivenom concentration in patients bitten by snakes in Uruguay.
    Morais V; Negrín A; Tortorella MN; Massaldi H
    Toxicon; 2012 Nov; 60(6):990-4. PubMed ID: 22819686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antivenom treatment in arachnidism.
    Isbister GK; Graudins A; White J; Warrell D
    J Toxicol Clin Toxicol; 2003; 41(3):291-300. PubMed ID: 12807312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.